Hot AI Mandate: Newly Established US-based VC Invests In AI-enabled Digital Health Technologies

3 May

A newly established venture capital firm founded in 2020 and is based in Palo Alto, CA. The firm’s first fund recently had its first close at $25M, and is actively seeking early-stage investment opportunities in life sciences and healthcare sectors. The firm is focused on emerging companies in pre-seed / seed rounds and will participate in Series A at the maximum. Currently, the firm is focused on USA-based companies, but can dedicate up to 20% of their fund to invest outside of the USA.

The firm invests in 4 main focus areas, ordered by priority: (1) biotech (40%), which includes biomarkers, liquid biopsies, cell therapy, smart packaging, drug delivery, next generation sequencing, omics; (2) digital health (30%), which includes wearables, diagnostics, services, AI-enabled approaches, management, fitness, digital therapy; (3) medtech (20%), which includes smart devices, smart lens, breath biopsy, 3D printing, in vitro diagnostics, surgical robotics, laser therapy; (4) health edtech (10%), which includes personalized learning, med. professional development, immersive learnings (e.g., VR), wellness. The firm plans to expand their investment capabilities in medtech, as they have recently made great investments in this space. The firm is indication agnostic, and is open to all opportunities including oncology, cardiovascular, infectious, metabolic, neurological, and rare/orphan diseases.

The firm seeks to work with companies backed by a management team with deep domain expertise and technologies that are backed by solid IP. The firm prefers to act as a follow-on, but will seek to lead more investment rounds in the future.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

Live Investor Q&A at Digital RESI

29 Apr

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

Since its inception, the Innovator’s Pitch Challenge (IPC) has quickly become a popular feature in our digital Redefining Early Stage Investments (RESI) conferences. The IPC is a twist on virtual pitch sessions, featuring a live Q&A session with active investors that attendees can join. Also included is a dedicated webpage on the RESI Live Agenda for each participating company, with marketing collateral that registered attendees can use to learn more about each pitching company.

Curious to know what the investor Q&A is like? Check out this short video below of Thomas Forest-Farb, CEO and Co-Founder of Thrive Bioscience, who won first place at Digital RESI March:

RESI has made extensive efforts to showcase innovative technologies across the globe. Do not miss this opportunity to be featured at Digital RESI, June 8-10. Increase exposure and engage with relevant investors and industry partners that can lead to lasting connections! Applications are due May 14, but apply by May 7 to save on early bird rates!               

The Roles of a Lifetime

29 Apr

By Rory McCann, Marketing Manager & Conference Producer, LSN

Eran is very active in the world of early-stage startups and fundraising within life science and is a recent contributor to the Redefining Early Stage Investments (RESI) community. Eran speaks with us about the value he’s found at RESI and how his many roles helped him make the most of his experience and add value to others. 

Digital RESI takes place June 8-10. There’s still time to save on early bird rates, sign up by May 7 to save!

The Who’s Who at the Digital RESI June Service Provider Showcase

29 Apr

By Ashley Zborowski, Director of Business Development, LSN

The Redefining Early Stage Investment (RESI) Service Provider Showcase helps companies gain unprecedented visibility into the early-stage life science community and leverages Life Science Nation (LSN)’s close-knit network of key decision-makers to make promising connections with future clients.  Service providers are an important asset in the fundraising ecosystem, and this new program is designed to increase their exposure to the RESI community.

Digital RESI, June 8-10, proudly features service providers advancing early-stage startups within drugs, devices, diagnostics, and digital health. Often the unsung heroes of fundraising startups, these powerful partnerships are essential in commercializing, building teams, conducting research, manufacturing, and so much more! Meet and get to know some featured service providers at Digital RESI June, and contact us to learn more about this special offer.

MERIT

image002MERIT is an innovative specialty CRO providing clinical trial data collection and interpretation in the ophthalmology and respiratory disciplines. Our portfolio of solutions offers deep clinical expertise, unique technology, and exceptional service for our partners, sponsors, and CROs.

PharmaDirections

pharmadirections-logoAt PharmaDirections, gain access to top talent without the cost or risk of a full-time, in-house team. More than just a consultant or outside vendor, we are an extension of your team and are accountable for all aspects of a project, from discovery to regulatory approval.

SPH Phililab

logosph-phililab-purple-english-600x131-1SPH Phililab an innovation pharmaceutical company that develop, registrar, and manufacture generic and modified new drug product in USA and China. Our product portfolio focuses on the two largest pharmaceutical markets in the world, plus our unique background of management team and scientists made us a pioneer as an international player in the pharmaceutical industry.

Hot Investor Mandate: Healthcare Venture Fund with USA & Asia Offices Invests in Global Startups in Life Sciences & Digital Health, Including Platform Technologies

29 Apr

An early-stage healthcare venture fund with teams based in USA and Asia looks to invest in visionary teams and cutting-edge technologies in both life science and digital health solutions.

The firm’s philosophy is not to take a one-size-fits-all approach to investing. The firm draws from their domain expertise and diversified experiences across the full healthcare spectrum to cover both Biopharma and Digital Health sectors. The firm’s aim is to support companies that can achieve differentiated therapeutic results through truly novel approaches. Combining scientific rigor and strategic connections within our network, the firm provides guidance and add value to our portfolio companies as they grow. The firm is seeking to work with companies from late Seed to Series B, and is open to global opportunities.

The firm is focused on two main investment themes:

(1) Life Sciences – the firm looks for sound scientific principles and seek innovative approaches, including breakthrough medicines and platform technologies. The firm’s key areas of interest include neurological diseases, metabolic diseases, and infectious diseases. The firm’s investment team engages with entrepreneurs and companies from early pre-clinical development where there is compelling science with cell and/or animal model proof of concept data and invests through pre-clinical and early clinical proof of concept stages;

(2) Digital Health / Bio IT

Digital health is a transformational area in healthcare. The firm looks for technology platforms that enable pertinent scientific insights into drug development and design or enhanced delivery of care from providers to patients. Key areas of interest include synthetic biology, machine learning for drug discovery (proteomics and metabolomics), and tools that help reduce healthcare costs.

The firm is looking for experienced management teams with strong scientific expertise and management skills.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Publicly Traded Biotech Seeks In-Licensing & Other Partnership Opportunities in Oncology & Immuno-Oncology

29 Apr

A publicly traded company focused on oncology therapeutics is seeking therapeutic opportunities in the oncology space. The firm is looking to partner and collaborate as well as in-license, but is primarily seeking partnerships. The firm seeks assets that have at the very least cellular proof of concept, but prefers companies to have some animal data or are approaching pre-IND studies. The firm is also willing to partner with unique and differentiated drug discovery platform companies. The firm will partner globally, but primarily partners with US and Europe-based companies.

The firm is interested only in oncology and immuno-oncology assets in high unmet tumor indications including RCC and HCC. For modality, the firm is interested only in small molecule and biologics. The firm is willing to consider therapeutics targeting both solid and liquid tumors. The firm will also partner with drug discovery companies, such as those using AI-based technologies to identify new therapeutic biology, as well as platform companies.

The firm will only partner with companies that have a strong IP position and a clear differentiating discovery and development strategy. The firm looks for startups with unique “First-in-Class” therapeutics and platforms.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Private Fund with USA & China LPs Invests Up to $10M In Clinical Stage Life Science Companies, Open to All Sectors & Indications

29 Apr

A private investment firm based in USA and Asia with limited partners including institutional investors from US and China, typically invests $5-10M in businesses from Series A to pre-IPO and public traded companies. The firm is open to leading or following a syndicated round. The firm is now seeking opportunities in North America.

The firm invests across therapeutics, medical devices, diagnostics, platform technologies, and healthcare IT and is looking for companies that are top 3 in their niche sector. Within therapeutics, the firm prefer clinical stage projects. The firm is opportunistic in terms of disease areas including orphan indications. Within device and diagnostics, the firm prefers post-prototype products with clinical validation.

The firm may request board representation or board observer ship on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →